Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.09%. A quarter ago, it was expected that this company would post a loss of $0.44 per share when it actually produced a loss of $0.39, delivering a surprise of 11.36%.Over the last four quarters, the company ha ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPEUTICS, INC. Washington, D.C. 20549 (Exact name of registrant as specified in its Charter) (State or other jurisdiction of incorporation or organization) 26 Landsdowne Street UNITED STATES SECURITIES AND EX ...

Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023 ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Restart of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) underway ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., – February 27, 2024 – Fulcrum Therapeutics, Inc. ® ( ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Financial Officer Iain Fraser - Interim Chief Medical Officer Conference Call Participants Benazir Ali - Stifel Joe Schwartz - Leerink Partners Edward Tenthoff - Piper Sandler Matthew Hagood - Oppenheimer Operator Good morning and welcome to Fulcrum Therapeutics Third Quarter 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) (617) 651-8851 (Registrant's telephone number, including area code) For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THER ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alexander Sapir - President and Chief Executive Officer Iain Fraser - Interim Chief Medical Officer Gregory Tourangeau - Principal Accounting Officer Conference Call Participants Benazir Ali - Stifel Joseph Schwartz - Leerink Partners Edward Tenthoff - Piper Sandler Matthew Hagood - Oppenheimer Judah Frommer - Credit Suisse Operator Good morning and ...

• Muscle fat infiltration (MFI): Measure of muscle health motion Tissue infiltration contributes to the loss of function by altering biomechanical properties 0% • MFF is an indicator of FSHD-affected muscles with a strong correlation to clinical function / disability Illustrative Normal-Appearing Intermediate End-stage Arjomand J, et al. Facioscapulohumeral muscular dystrophy (FSHD) voice of the patient report. Published November 5, 2020. Accessed March 1, 2021 8 10 p38α/β ON Losmapimod, a Highly Selective ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other jurisdiction of incorporation or organization) 26 Landsdowne Street Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Robert J. Gould - President and CEO Iain Fraser - Interim Chief Medical Officer Conference Call Participants Edward Tenthoff - Piper Sandler Joseph Schwartz - SVB Securities Unidentified Analyst - Goldman Sachs Matthew Biegler - Oppenheimer Judah Frommer - Crédit Suisse Operator Good morning and welcome to the Fulcrum Therapeutics First Quarter 2023 F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common stock, par value $0.001 per share | FULC | The Nasdaq Global Market | or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo ...